Skip to main content
IDXXNasdaqinactive

IDEXX LABORATORIES INC /DE

·Westbrook, ME, United States·CEO: Mr. Michael G. Erickson Ph.D.

IDXX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for IDXX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

7.5/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

$44.34B

Cash Runway

Lead Asset

Next Catalyst

Financial data as of Mar 31, 2026.

Run IDEXX LABORATORIES INC /DE through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available IDEXX LABORATORIES INC /DE facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health8.1

D/E 1.18 · 1% dilution

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider Signal4.3

0 buys · 1 sell (180d)

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1,303

Total value held

$40.38B

HolderSharesValue
vanguard capital management llc10,365,014$5.82B
blackrock, inc.8,365,553$4.70B
vanguard portfolio management llc3,910,863$2.20B
state street corp3,674,185$2.06B
geode capital management, llc2,660,999$1.50B
bamco inc /ny/1,633,367$917.8M
bank of new york mellon corp1,504,532$845.4M
morgan stanley1,315,954$739.4M
blair william & co/il946,336$531.7M
northern trust corp911,893$512.4M

Showing top 10 of 1,303 institutional holders of IDEXX LABORATORIES INC /DE. Open the full 13F history after sign-in.

Short Interest

as of May 21, 2026
% of float
3.0%
Days to cover
3.8
Shares short
2,082,179
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

IDXX short interest

Governance

Frequently asked questions

Who is the CEO of IDEXX LABORATORIES INC /DE?

Mr. Michael G. Erickson Ph.D. is the chief executive officer of IDEXX LABORATORIES INC /DE (IDXX).

Where is IDEXX LABORATORIES INC /DE headquartered?

IDEXX LABORATORIES INC /DE (IDXX) is headquartered in Westbrook, ME, United States.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.